Showing results (561-570 of 610) with videos related to
Sort By:
Pageof 61
Human Gene Therapy|July 13, 2000
Percutaneous gene therapy using recombinant adenoviruses encoding human herpes simplex virus thymidine kinase, human PAI-1, and human NOS3 in balloon-injured porcine coronary arteriesO Varenne, P Sinnaeve, H Gillijns, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|October 13, 2001
L-arginine administration reduces neointima formation after stent injury in rats by a nitric oxide-mediated mechanismP Vermeersch, Z Nong, E Stabile, et al.The Journal of Pharmacology and Experimental Therapeutics|October 1, 1984
Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cellsD Collen, J M Stassen, B J Marafino, et al.Journal of the American College of Cardiology|August 1, 1993
Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapyF Van de Werf, L Janssens, T Brzostek, et al.Circulation|March 1, 1988
Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparationH K Gold, B S Coller, T Yasuda, et al.Circulation|May 1, 1984
Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinaseB E Sobel, E M Geltman, A J Tiefenbrunn, et al.American Heart Journal|August 1, 1997
Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarctionS Vanderschueren, J Dens, P Kerdsinchai, et al.Klinische Wochenschrift|January 1, 1988
[Randomized double-blind study comparing tissue-type plasminogen activator with placebo in acute myocardial infarct]W Bleifeld, M Verstraete, R W Brower, et al.Circulation|February 1, 1991
Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trialJ M Gore, M Sloan, T R Price, et al.Nature|March 31, 1994
Physiological consequences of loss of plasminogen activator gene function in miceP Carmeliet, L Schoonjans, L Kieckens, et al.Pageof 61